Reply to D Fuchs et al
Dear Sir:
We thank Fuchs et al for their kind letter. Unfortunately, their recent work (1) was not available to us and thus could not be included in the article of ours to which they refer (2) . Essentially, both works coincided in many respects, given the previous data in this field (3) . The improvement in vitamin B-12 concentrations in HIV-infected patients after highly active antiretroviral therapy (HAART) was expected because of the relation of vitamin B-12 concentrations with neutrophil counts and cobalophilin (R-binder). Neutrophil, CD4
ϩ , CD8 ϩ , and hemoglobin concentrations also increased as part of a general improvement in health after HAART. This general improvement also included increases in immune system activation markers. Nevertheless, the suggestion of "an amelioration of hyperhomocysteinemia" needs further comment. In our work, this amelioration could not be shown because homocysteine concentrations were not investigated in the group of patients before HAART treatment. Moreover, some studies in the pre-HAART era did not find a difference in homocysteine concentrations between HIV-infected patients and healthy subjects, regardless of vitamin B-12 concentrations.
Fuchs et al suggest an important role for antioxidants, Sadenosylmethionine, and homocysteine in the pathogenesis of vitamin B-12-related abnormalities (4, 5) . Moreover, there is some evidence of antioxidant disturbances in HIV infection (6) . Although the involvement of oxidative stress in neurologic disturbances due to vitamin B-12 deficiency arouses considerable interest, such involvement has yet to be shown. In this regard, other hypotheses have been proposed for the pathogenesis of cobalamin neuropathy, such as a decline in formate synthesis, disturbances in methylmalonic acid metabolism, and the action of inactive cobalamin analogues (7). 
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